NUT carcinoma (midline carcinoma with NUTM1 rearrangement)

What changed: NUT carcinoma (midline carcinoma with NUTM1 rearrangement)

Cancer page →

Every dated change on the records linked to NUT carcinoma (midline carcinoma with NUTM1 rearrangement), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Milestone6This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-10This recordNUT carcinoma (midline carcinoma with NUTM1 rearrangement)
Facts on this page last checked
When this page itself was last checked or edited.

2021 · 1

2021MilestoneNUT carcinoma (midline carcinoma with NUTM1 rearrangement)
International NUT Carcinoma Registry outcomes
Chau and colleagues, JCO: fusion partner and initial treatment predict survival.

2016 · 1

2016MilestoneEpigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)
First BET inhibitor responses in patients
Birabresib (OTX015) and molibresib phase 1 cohorts.

2010 · 1

2010MilestoneNUT carcinoma (midline carcinoma with NUTM1 rearrangement)
BET inhibitor JQ1 induces differentiation of NUT carcinoma cells
Filippakopoulos and colleagues, Nature: proof of concept for BET inhibition.

2009 · 1

2009MilestoneNUT carcinoma (midline carcinoma with NUTM1 rearrangement)
NUT immunohistochemistry validated
Haack and colleagues: highly specific antibody enables diagnosis.

2003 · 1

2003MilestoneNUT carcinoma (midline carcinoma with NUTM1 rearrangement)
BRD4-NUT fusion cloned
French and colleagues identify the fusion gene.

1991 · 1

1991MilestoneNUT carcinoma (midline carcinoma with NUTM1 rearrangement)
First reports of aggressive midline carcinoma with t(15;19) in children
A milestone in how this cancer is treated.